Litigation
Mar. 1, 2011
Drug Companies Face Off Over HIV Drug
GlaxoSmithKline argued in court Monday that Abbott Laboratories violated antitrust laws when it raised the price of a booster drug necessary for GSK's anti-HIV medication to work properly.
Daily Journal Staff Writer
By the time GlaxoSmithKline launched its HIV drug Lexiva in November 2003, it had spent six years and $750 million developing the drug.
The company also paid $325 million to its competitor Abbott Laboratories for the right to co-promote Lexiva with Abbott's drug, Norvir, a so-called "booster" drug that raised the efficacy of other HIV drugs when used in small doses. Lexiva's success...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In